Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Invested Capital (2016 - 2025)

Historic Invested Capital for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $950.2 million.

  • Ligand Pharmaceuticals' Invested Capital rose 1295.72% to $950.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $950.2 million, marking a year-over-year increase of 1295.72%. This contributed to the annual value of $830.5 million for FY2024, which is 1848.56% up from last year.
  • Ligand Pharmaceuticals' Invested Capital amounted to $950.2 million in Q3 2025, which was up 1295.72% from $828.5 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Invested Capital ranged from a high of $950.2 million in Q3 2025 and a low of $597.5 million during Q4 2022
  • Over the past 5 years, Ligand Pharmaceuticals' median Invested Capital value was $795.5 million (recorded in 2025), while the average stood at $786.9 million.
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 2751.95% in 2023, then surged by 2594.45% in 2024.
  • Ligand Pharmaceuticals' Invested Capital (Quarter) stood at $821.3 million in 2021, then dropped by 27.24% to $597.5 million in 2022, then grew by 17.31% to $700.9 million in 2023, then grew by 18.49% to $830.5 million in 2024, then increased by 14.41% to $950.2 million in 2025.
  • Its Invested Capital was $950.2 million in Q3 2025, compared to $828.5 million in Q2 2025 and $795.5 million in Q1 2025.